Minister says Indian pharma sector can grow to 65 bln USD by 2024
Indian minister for chemicals and fertilizers D. V. Sadananda Gowda Thursday said the country was one of the largest manufacturers and exporters of generic medicines across the world.
"Indian pharma sector can grow to 65 billion U.S. dollars industry by 2024," Gowda said. "We have recently launched schemes for the development of seven mega parks-three bulk drug parks and four medical device parks across the country."
"New manufacturers will be eligible for the Production Linked Incentive (PLI) Scheme under which they will be eligible for financial incentives on basis of their sales for the first five to six years."
During the initial phase, he said, Hydroxychloroquine (HCQ) and Azithromycin was identified as one of medicines under treatment protocol for COVID-19 in emergency cases.
The minister said India earned the reputation of reliable suppliers of medicines as it supplied these medicines to more than 120 countries across the world.
Addressing a video conference FICCI LEADS 2020, the minister highlighted that India is one of the largest manufacturers and exporter of generic medicines across the world.
Gowda also said the market size of chemicals and petrochemicals sector in India is around 165 billion U.S. dollars, and the size was expected to grow up to 300 billion U.S. dollars by 2025.
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
24th Pharma Asia International Exhibition & Conferences to Open in Karachi, Pakistan
-
Pharma Asia 2026: Bringing the Global Pharmaceutical Industry to Pakistan
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
Recommend Reading
-
Russia’s Farm Trade Model Shows Strain
-
India Issues Final Anti-Dumping Ruling on Chinese TDQ, with Duties Up to US$549 per Ton
-
Global Countries Impose Tariffs on Chinese Chemical Products
-
Saudi East-West Oil Pipeline Shut Down After Attack, Disrupting 4 Million bpd of Oil Flow
-
Chemours Sells Its Former Titanium Dioxide Site in Taiwan: Turning a “White Powder” Factory into “Wind Power Real Estate” for $360 Million—Buying Not Cash, But Breathing Room
-
Supply-Demand Struggle Continues, Acrylic Market Remains Weak
-
Coke Market Stably Strong, Price Increase Implemented at Midnight on the 26th
-
Insufficient Downstream Demand Leaves Cyclohexane Price Gains Weak in September
-
EFSA Reviews Clodinafop Risk
-
A Chart to Understand Lithium Carbonate VS Lithium Hydroxide, the Divergence of the Two Lithium Salts in China's Lithium Battery Industry